Drugs.com - Pharma Industry News

Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM

MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use, according to a...

Mar 10, 2025 - 18:46
 0
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use, according to a...
Read More

Tags:

Previous Article

People With Disabilities Often Feel Disrespected by Health Care Workers

Next Article

Eric Emanuel opens newly renovated boutique in SoHo, New York

Related Posts

Ultraprocessed Food Consumption in Early Childhood Tied to Obesity

Ultraprocessed Food Consumption in Early Childhood Tied...

Feb 9, 2025  0

Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC

Dual-Targeted Therapies Plus Chemo Improve Objective Re...

Feb 9, 2025  0

Mental Health Disparities Seen Among Sexual, Gender Minority Populations

Mental Health Disparities Seen Among Sexual, Gender Min...

Feb 9, 2025  0